
- Applied Clinical Trials-10-01-2011
- Volume 20
- Issue 10
Sponsors Show a Preference for Large CROs
Industry Standard Research has recently published new research titled "Post-marketing Safety Market Dynamics," which deeply dives into the growth and decline of study conduct and outsourcing in the post-marketing safety arena.
Industry Standard Research has recently published new research titled "Post-marketing Safety Market Dynamics," which deeply dives into the growth and decline of study conduct and outsourcing in the post-marketing safety arena. As with much the company's research, a portion of the work was dedicated to exploring the attitudes and use of service providers in the space. Sponsors identified different types of service providers as "Best Fit," depending on the specific service. And the pattern of winners and losers is variable across all five services tested (Phase IV studies, Signal Management Activities, Risk Management Programs, EU QPPV Service, and Scientific Literature Searches).
However, in spite of their lagging position for signal management activities (and some of the others tested) sponsors continue to express a preference for using large CROs.
Large CROs were voted the best fit for non-interventional Phase IV studies.
What should be made of this dynamic? Why should a buyer prefer to use members of a group they believe are a poor fit for the service, relatively speaking?
Perhaps it is the old adage that "nobody gets fired for hiring IBM." But for our industry it's "nobody gets fired for hiring Quintiles/PPD/PAREXEL/Covance/ICON." Or perhaps in spite of a theoretical good fit, the scope of the work is outgrowing the specialists' capabilities. Your thoughts? Send them to
—Industry Standard Research,
Articles in this issue
almost 15 years ago
Applied Clinical Trials Digital Edition - October 2011almost 15 years ago
Here Comes the Sun(shine Act)almost 15 years ago
Cardiac Safety in Clinical Trialsalmost 15 years ago
Business and News Update October 2011almost 15 years ago
Debate Grows Over Comparative Efficacy Trialsalmost 15 years ago
The Power and Pitfalls of Aggregate Dataalmost 15 years ago
Document Managementalmost 15 years ago
Technology Helps Trim Reimbursement Timesalmost 15 years ago
FDA, Sponsors Gear Up for User-Fee Actionalmost 15 years ago
Staying Vigilant on EU Pharmacovigilance


